OpenAI lists unannounced gpt-rosalind-discovery on its API pricing page

#What happened

OpenAI's API pricing page now lists a new model called gpt-rosalind-discovery under a "Life sciences models" section, right beside gpt-rosalind-research. The company has not announced it: there is no blog post, help article, or system card yet. The listing was first spotted and shared on X today (October 10, 2026) by the AI Tracker Bot at TestingCatalog.

#Why it matters

Pricing is identical to gpt-rosalind-research: $5 per million input tokens, $0.50 per million cached input tokens, and $25 per million output tokens. The pricing page notes that billing for gpt-rosalind-research began October 5, 2026, cache-write pricing does not apply, and access stays restricted to approved internal research through OpenAI's trusted-access program. The name points at drug discovery, and OpenAI's own pricing page says eligible organizations keep getting access to "the latest GPT-Rosalind models as they're released," which reads as a family rather than a one-off. For context, GPT-Rosalind launched in April 2026 as OpenAI's frontier reasoning model for biology, drug discovery, and translational medicine, with Amgen, Moderna, the Allen Institute, and Thermo Fisher Scientific named as early partners. Its exact purpose is still unconfirmed; anything beyond the listing itself is speculation for now.

#Sources

• https://www.testingcatalog.com/openai-lists-new-gpt-rosalind-discovery-model-in-docs/

Verified October 10, 2026.